NovoCure Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.
| Earnings Date | 2/25/2027 |
As of September 30, 2026, NovoCure Ltd. has 116.91M shares outstanding.
| Shares Outstanding | 116.91M |
As of September 30, 2026, NovoCure Ltd. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.49 |
| Quick Ratio | 2.30 |
| Debt / Equity | 66.04 |
| Debt / EBITDA | -2.15 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a negative return on equity (ROE) of -35.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.12, reflecting losses generated across the asset base. The company generates approximately 398,760.02 in revenue per employee across its workforce of 1,605.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.18 indicates how many times NovoCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -35.18 |
| Return on Assets (ROA) | -11.12 |
| Revenue Per Employee | 398,760.02 |
| Employee Count | 1,605.00 |
| Inventory Turnover | 4.18 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. recorded an income tax benefit of -7.78M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -115.18M and -107.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -7.78M |
Over the twelve months ended September 30, 2026, NovoCure Ltd. generated 640.01M in revenue and converted that into -107.40M in net income, yielding earnings per share of -0.94. EBITDA reached -94.83M, while operating income came in at -109.89M.
| Revenue | 640.01M |
| Gross Profit | 492.91M |
| Operating Income | -109.89M |
| Pretax Income | -115.18M |
| Net Income | -107.40M |
| EBITDA | -94.83M |
| EBIT | -109.89M |
| Earnings Per Share (EPS) | -0.94 |
As of September 30, 2026, NovoCure Ltd. holds 408.93M in cash and equivalents against 204.30M in total debt, resulting in a net debt position of 87.88M. Total book value stands at 309.35M, with working capital of 355.44M providing operational flexibility.
| Cash & Cash Equivalents | 408.93M |
| Total Debt | 204.30M |
| Net Debt | 87.88M |
| Equity (Book Value) | 309.35M |
| Book Value Per Share | 2.65 |
| Working Capital | 355.44M |
NovoCure Ltd. produced -637,020.60 in operating cash flow over the twelve months ended September 30, 2026. After subtracting -21.07M in capital expenditures, free cash flow totaled -21.71M - equivalent to -0.19 per share.
| Operating Cash Flow | -637,020.60 |
| Capital Expenditures | -21.07M |
| Free Cash Flow | -21.71M |
| FCF Per Share | -0.19 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a gross margin of 77.02, reflecting its pricing power and cost economics. The operating margin of -17.17 and net profit margin of -16.78 provide insight into operational efficiency.
| Gross Margin | 77.02 |
| Operating Margin | -17.17 |
| Pretax Margin | -18.00 |
| Profit Margin | -16.78 |
| EBITDA Margin | -14.82 |
Already premium?